SCHEMBL2478436

SCHEMBL2478436

CC(C)(C)OC(=O)Nc1ccccc1NC(=O)c1ccc(C(CCOCCO)NC(=O)Nc2ccc3c(c2)CCC3)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 14/20 0.41
RAB9A P51151 14/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
NFKB1 P19838 3/20 0.41
NFKB2 Q00653 3/20 0.41
RELA Q04206 3/20 0.41
TP53 P04637 3/20 0.41
GAA P10253 2/20 0.41
HTT P42858 1/20 0.41
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
TRPV1 Q8NER1 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
HDAC1 Q13547 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2493868 0.92 NPC1 (0.42) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2477559 0.88 NPC1 (0.42) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL3829655 0.87 NPC1 (0.44) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2478122 0.86 UTS2R (0.42) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2477989 0.86 KMT2A (0.45) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2476207 0.83 NPC1 (0.41) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL3832630 0.80 NPC1 (0.51) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL3834371 0.80 UTS2R (0.43) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2472984 0.79 UTS2R (0.48) NPC1RAB9ACASP3SENP7ALDH1A1
SCHEMBL3829610 0.79 ROCK2 (0.46) HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 NPC1 989/4885RAB9A 1942/4885SMN1; SMN2 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.